RPRX
Royalty Pharma plc NASDAQ Listed Jun 16, 2020$50.20
After hrs
$51.65
+1.69%
Mkt Cap $21.5B
52w Low $32.15
92.6% of range
52w High $51.65
50d MA $47.64
200d MA $40.77
P/E (TTM)
21.2x
EV/EBITDA
15.3x
P/B
2.2x
Debt/Equity
1.4x
ROE
20.4%
P/FCF
6.7x
RSI (14)
—
ATR (14)
—
Beta
0.39
50d MA
$47.64
200d MA
$40.77
Avg Volume
3.4M
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
110 East 59th Street · New York City, NY 10022 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | BMO | 1.29 | 1.46 | +13.2% | 44.25 | -0.0% | +1.2% | +2.1% | +2.6% | +2.5% | +1.9% | — |
| Nov 5, 2025 | BMO | 0.99 | 1.17 | +17.7% | 40.42 | +0.6% | +0.9% | -4.6% | -4.7% | -3.6% | -2.1% | — |
| Aug 6, 2025 | BMO | 1.03 | 1.14 | +10.7% | 37.12 | +0.0% | -0.3% | +1.2% | -2.5% | -3.4% | -1.8% | — |
| May 8, 2025 | BMO | 0.95 | 1.06 | +11.2% | 33.10 | +0.4% | +0.2% | +0.8% | -0.8% | -2.4% | +0.1% | — |
| Feb 11, 2025 | BMO | 0.99 | 1.15 | +16.2% | 32.25 | +0.1% | +0.3% | +0.7% | +0.3% | +1.9% | +1.1% | — |
| Nov 6, 2024 | BMO | 0.93 | 1.04 | +12.1% | 26.64 | +1.4% | -0.5% | -1.6% | -1.1% | -2.4% | -3.0% | — |
| Aug 8, 2024 | BMO | 0.96 | 0.96 | -0.5% | 26.15 | +0.7% | +0.4% | +1.1% | +2.7% | +1.9% | +4.8% | — |
| May 9, 2024 | BMO | 0.99 | 0.98 | -0.7% | 27.97 | +1.9% | +0.4% | +1.5% | +0.4% | +0.9% | -0.3% | — |
| Feb 15, 2024 | BMO | 1.01 | 1.15 | +13.9% | 30.03 | +0.0% | -0.4% | +0.9% | +4.0% | +3.3% | +3.3% | — |
| Nov 8, 2023 | BMO | 0.81 | 0.79 | -2.5% | 27.62 | +0.9% | -0.8% | -1.4% | -1.8% | -0.4% | -2.2% | — |
| Aug 8, 2023 | BMO | 0.83 | 0.85 | +2.4% | 30.55 | +0.6% | +0.0% | +0.1% | -0.3% | -1.4% | -2.5% | — |
| May 9, 2023 | BMO | 1.32 | 1.60 | +21.2% | 33.99 | -0.1% | -0.4% | +1.5% | +1.6% | +1.0% | -2.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | UBS | Maintains | Buy → Buy | — | $49.30 | $49.59 | +0.6% | +0.4% | +0.9% | +0.7% | +0.2% | +0.7% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $48.30 | $48.30 | +0.0% | -0.8% | +0.3% | +1.1% | +0.8% | +0.4% |
| Jan 30 | UBS | Upgrade | Neutral → Buy | — | $40.86 | $41.27 | +1.0% | +2.0% | +3.7% | +5.2% | +6.9% | +7.9% |
| Jan 27 | Citigroup | Maintains | Buy → Buy | — | $40.47 | $40.50 | +0.1% | +0.7% | -0.1% | +1.0% | +3.0% | +4.7% |
| Dec 11 | TD Cowen | Maintains | Buy → Buy | — | $38.26 | $38.30 | +0.1% | +1.4% | +0.3% | +0.7% | +0.3% | +0.1% |
| Oct 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $36.14 | $36.32 | +0.5% | -0.4% | -1.9% | -0.4% | +0.1% | +0.6% |
| Jul 22 | Citigroup | Maintains | Buy → Buy | — | $35.65 | $35.65 | +0.0% | +1.3% | +1.0% | +2.6% | +2.9% | +4.0% |
| Jul 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $35.87 | $36.00 | +0.4% | +0.7% | -0.1% | +1.0% | +1.8% | -0.8% |
| Oct 25 | Citigroup | Maintains | Buy → Buy | — | $27.28 | $27.35 | +0.3% | -1.2% | -0.1% | -0.5% | -0.3% | -1.0% |
| Aug 14 | Goldman Sachs | Maintains | Buy → Buy | — | $26.86 | $26.81 | -0.2% | -0.8% | +2.0% | +1.2% | +2.3% | +1.5% |
| Jul 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $25.73 | $25.96 | +0.9% | +3.9% | +4.0% | +3.6% | +7.6% | +9.2% |
| Jun 3 | UBS | Downgrade | Buy → Neutral | — | $27.41 | $27.10 | -1.1% | -2.1% | -1.4% | -1.5% | -1.2% | +0.2% |
| Apr 12 | BofA Securities | Maintains | Buy → Buy | — | $29.05 | $29.06 | +0.0% | -2.9% | -2.8% | -5.5% | -5.0% | -4.0% |
| Feb 20 | Goldman Sachs | Maintains | Buy → Buy | — | $29.92 | $29.91 | -0.0% | +1.3% | +4.4% | +3.7% | +3.7% | +4.7% |
| Feb 20 | JP Morgan | Maintains | Overweight → Overweight | — | $29.92 | $29.91 | -0.0% | +1.3% | +4.4% | +3.7% | +3.7% | +4.7% |
| Nov 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $27.62 | $27.87 | +0.9% | -0.8% | -1.4% | -1.8% | -0.4% | -2.2% |
| Oct 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $26.93 | $26.95 | +0.1% | +0.8% | +0.6% | +3.4% | +3.8% | +5.8% |
| Aug 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.55 | $30.72 | +0.6% | +0.0% | +0.1% | -0.3% | -1.4% | -2.5% |
| Jul 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $30.05 | $30.26 | +0.7% | +2.2% | +4.1% | +2.2% | +2.3% | +2.0% |
| May 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $33.99 | $33.96 | -0.1% | -0.4% | +1.5% | +1.6% | +1.0% | -2.2% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $36.38 | $36.58 | +0.5% | -0.2% | +0.4% | -0.7% | +0.4% | -0.3% |
| Apr 6 | Tigress Financial | Maintains | Buy → Buy | — | $36.27 | $36.43 | +0.4% | +0.3% | +0.1% | +0.7% | -0.4% | +0.7% |
| Feb 16 | UBS | Maintains | Buy → Buy | — | $37.69 | $37.53 | -0.4% | -1.2% | +0.4% | -1.1% | -1.5% | -1.5% |
| Dec 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $43.01 | $42.85 | -0.4% | -2.5% | -2.0% | -1.6% | -2.9% | -1.9% |
| Nov 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $42.69 | $42.82 | +0.3% | +0.8% | +3.0% | +2.9% | -0.4% | -1.4% |
| Oct 18 | JP Morgan | Maintains | Overweight → Overweight | — | $41.78 | $42.21 | +1.0% | +0.6% | -1.8% | -2.2% | -1.8% | -1.2% |
| Sep 13 | Scotiabank | Maintains | Outperform → Outperform | — | $43.64 | $43.04 | -1.4% | -2.4% | -2.7% | -3.4% | -3.9% | -4.6% |
| Aug 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $42.45 | $42.60 | +0.4% | +1.6% | +2.9% | +3.5% | +2.9% | +4.1% |
| Jul 14 | Tigress Financial | Maintains | Buy → Buy | — | $42.39 | $42.33 | -0.1% | +1.9% | +3.6% | +3.1% | +3.0% | +1.5% |
| Jun 14 | UBS | Maintains | Buy → Buy | — | $38.46 | $38.34 | -0.3% | -0.7% | +0.2% | -0.4% | +2.3% | +4.3% |
| May 13 | Scotiabank | Maintains | Outperform → Outperform | — | $38.95 | $40.00 | +2.7% | +2.5% | +3.4% | +6.2% | +4.0% | +2.1% |
| Apr 27 | Goldman Sachs | Maintains | Buy → Buy | — | $41.83 | $42.19 | +0.9% | +2.8% | +4.1% | +1.8% | +1.2% | +2.1% |
| Apr 14 | JP Morgan | Upgrade | Neutral → Overweight | — | $42.44 | $43.18 | +1.7% | +3.9% | +3.9% | +4.1% | +4.2% | +2.7% |
| Apr 6 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $39.84 | $39.92 | +0.2% | +1.4% | +2.5% | +4.0% | +4.2% | +4.9% |
| Oct 29 | Citigroup | Upgrade | Neutral → Buy | — | $38.20 | $39.10 | +2.4% | +3.5% | +4.0% | -0.2% | +3.4% | +3.6% |
| Aug 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $38.73 | $38.67 | -0.2% | -1.2% | +0.9% | -0.0% | +0.4% | +0.7% |
| Jul 30 | Tigress Financial | Maintains | Buy → Buy | — | $38.25 | $38.32 | +0.2% | -0.1% | -2.7% | -1.5% | -3.9% | -2.6% |
| Nov 9 | UBS | Upgrade | Neutral → Buy | — | $40.24 | $42.86 | +6.5% | +1.8% | +0.9% | +0.2% | +1.0% | +4.7% |
| Jul 13 | JP Morgan | Maintains | Neutral → Neutral | — | $47.64 | $47.20 | -0.9% | -7.5% | -8.6% | -9.7% | -11.4% | -7.2% |
| Jul 13 | BofA Securities | Maintains | Buy → Buy | — | $47.64 | $47.20 | -0.9% | -7.5% | -8.6% | -9.7% | -11.4% | -7.2% |
| Jul 13 | Cowen & Co. | Maintains | Outperform → Outperform | — | $47.64 | $47.20 | -0.9% | -7.5% | -8.6% | -9.7% | -11.4% | -7.2% |
| Jul 13 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $47.64 | $47.20 | -0.9% | -7.5% | -8.6% | -9.7% | -11.4% | -7.2% |
| Jul 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $47.64 | $47.20 | -0.9% | -7.5% | -8.6% | -9.7% | -11.4% | -7.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | Coyne Terrance P.Off | EVP & CFO | Sell | 1,875 | $49.78 | $93K | 40,136 | -1.24% | +0.22% |
| Apr 28, 2026 | Coyne Terrance P.Off | EVP & CFO | Sell | 32,916 | $49.78 | $1.6M | — | -1.24% | +0.22% |
8-K · 2.02
!! High
Royalty Pharma plc -- 8-K 2.02: Earnings Results
Royalty Pharma reported Q1 2026 earnings on May 6, 2026, with results available in the accompanying press release for investor review and analysis.
May 6
8-K
Unknown — 8-K Filing
Revolution Medicines secured up to $1 billion in non-dilutive financing tied to daraxonrasib's FDA approval milestones, reducing capital needs while Royalty Pharma gains royalty upside if the drug achieves blockbuster sales.
Apr 13
8-K
Royalty Pharma plc Class A -- 8-K Filing
Royalty Pharma delivered strong 2025 performance with 16% portfolio receipt growth, record shareholder returns, and $2.6 billion in new royalty investments, demonstrating robust cash generation and strategic capital deployment.
Feb 11
Data updated apr 26, 2026 11:29pm
· Source: massive.com